Alembic Receives 'Hold' Rating, Shows Bullish Trend

Alembic, a smallcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO on November 6, 2023. This downgrade comes as the company's stock has been showing a low Debt to Equity ratio, averaging at 0 times. However, the stock is currently in a Bullish range and has shown a technical trend improvement since December 4, 2023, with a return of 6.87%. The majority shareholders of Alembic are the promoters, indicating their confidence in the company's performance. However, the company has shown poor long-term growth with a -0.63% annual growth rate in Net Sales over the last 5 years. In the recent quarter, the company's results have been flat with a decline in PAT(Q) at Rs 90.68 crore and NET SALES(Q) at Rs 32.28 crore. With a ROE of 11.3, Alembic currently has a very expensive valuation with a 1.1 Price to Book Value. However, the stock is trading at a fair value compared to its historical valuations. In the past year, the stock has generated a return of 25.90%, while its profits have risen by 60.1%. The PEG ratio of the company is 0.2, indicating a potential for future growth. Overall, while Alembic may not be a strong buy at the moment, it is still a company worth keeping an eye on for potential growth opportunities in the future. Investors should carefully consider all factors before making any investment decisions.